Loading clinical trials...

UNKNOWN

Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer

Accurate Prediction and Validation of Response to Neoadjuvant Chemotherapy in Cervical Cancer

NCT03229187•Huazhong University of Science and Technology

Summary

Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies. However, not all patients respond well to neoadjuvant chemotherapy. Knowing the therapeutic effect of the neoadjuvant chemotherapy before receiving it can not only reduce the economic burden, but also more importantly save time to take more suitable treatments. This study is undertaken to build specific molecular signatures to predict the effects of neoadjuvant chemotherapy.

Eligibility

Age

18 - 70 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Untreated cervical cancer with FIGO stage Ib-IIb
•Measurable lesions
•Possible to radical hysterectomy
•Age: 18 and older
•Karnofsky Performance Status≥ 70.
•WBC \> 3,000/mm³, Hb \> 9.0g/dl, Platelet \> 100,000 /mm³, SGOT/SGPT \< 60 IU/L, T-Bil \< 1.5 mg/dL, Cr \< 1.2 mg/dL, PaO2 \> 80 torr, normal ECG
•Written informed consent

Exclusion Criteria

•Previous history of cancer
•Patients with previous treatment
•Patients without information of clinical risk factors
•Patients who have active infection

Locations (1)

Tongji Hospital

Wuhan, Hubei, China

Key Dates

Start Date

January 1, 2016

Primary Completion Date

September 30, 2020

Completion Date

September 30, 2020

Last Updated

June 16, 2020

Enrollment

240

ESTIMATED participants

Conditions

Uterine Cervical NeoplasmsCervical CancerUterine Cervical Cancer

Contacts

Ma Ding, M.D.

CONTACT

86-27-8362681 dma@tjh.tjmu.edu.cn

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642

Early Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial Carcinoma+25 more

View study

RECRUITINGPHASE1/PHASE2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05639972

HPV-Associated Cervical CarcinomaHPV-Related Carcinoma+15 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 16, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer

Inclusion Criteria

Exclusion Criteria

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Rice Technologies for Cervical Cancer Screening and Diagnosis